Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Neijt

Showing results (81-90 of 95) with videos related to

Pageof 10
Sort By:
The Netherlands Journal of Medicine|December 1, 1989
Mitoxantrone, methotrexate, and 5-fluorouracil (MMF) in hormone-refractory advanced breast cancerJ W Nortier, J P Neijt, P A Bleeker, et al.
European Journal of Cancer & Clinical Oncology|July 1, 1987
Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian CancerM E van der Burg, W W ten Bokkel Huinink, R Vriesendorp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancerJ P Neijt, S A Engelholm, M K Tuxen, et al.
Lancet (London, England)|October 31, 1987
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatmentA T van Holten-Verzantvoort, O L Bijvoet, F J Cleton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Palliative pamidronate treatment in patients with bone metastases from breast cancerA T van Holten-Verzantvoort, H M Kroon, O L Bijvoet, et al.
NMR in Biomedicine|June 1, 1990
31P NMR study of cisplatin- and doxorubicin-induced changes in tumour metabolism in rats with a cisplatin-sensitive or -resistant immunocytomaP E Sijens, C J van Echteld, R H van Rijssel, et al.
Cancer Treatment Reviews|June 1, 1988
Carboplatin in combination therapy for ovarian cancerW W ten Bokkel Huinink, M E van der Burg, A T van Oosterom, et al.
Seminars in Oncology|November 5, 1997
Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysisJ P Neijt, S A Engelholm, P O Witteveen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1987
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinomaJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian CancerJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
Pageof 10

Showing results (81-90 of 95) with videos related to

Sort By:
Pageof 10
The Netherlands Journal of Medicine|December 1, 1989
Mitoxantrone, methotrexate, and 5-fluorouracil (MMF) in hormone-refractory advanced breast cancerJ W Nortier, J P Neijt, P A Bleeker, et al.
European Journal of Cancer & Clinical Oncology|July 1, 1987
Teniposide (VM-26) in patients with advanced refractory ovarian cancer: a phase II study of the Netherlands Joint Study Group for Ovarian CancerM E van der Burg, W W ten Bokkel Huinink, R Vriesendorp, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2000
Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancerJ P Neijt, S A Engelholm, M K Tuxen, et al.
Lancet (London, England)|October 31, 1987
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatmentA T van Holten-Verzantvoort, O L Bijvoet, F J Cleton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1993
Palliative pamidronate treatment in patients with bone metastases from breast cancerA T van Holten-Verzantvoort, H M Kroon, O L Bijvoet, et al.
NMR in Biomedicine|June 1, 1990
31P NMR study of cisplatin- and doxorubicin-induced changes in tumour metabolism in rats with a cisplatin-sensitive or -resistant immunocytomaP E Sijens, C J van Echteld, R H van Rijssel, et al.
Cancer Treatment Reviews|June 1, 1988
Carboplatin in combination therapy for ovarian cancerW W ten Bokkel Huinink, M E van der Burg, A T van Oosterom, et al.
Seminars in Oncology|November 5, 1997
Paclitaxel (175 mg/m2 over 3 hours) with cisplatin or carboplatin in previously untreated ovarian cancer: an interim analysisJ P Neijt, S A Engelholm, P O Witteveen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1987
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinomaJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian CancerJ P Neijt, W W ten Bokkel Huinink, M E van der Burg, et al.
Pageof 10